Relationship between Changes of Serum Vascular Endothelial Growth Factor and Folate Receptor- α Levels and Clinical Efficacy of Toripalimab in Patients with Bladder Cancer

CONCLUSIONS: The changes of serum VEGF and FR-α levels in patients with bladder cancer can predict the therapeutic effect of toripalimab. Before clinical treatment, the detection of the two indicators must be strengthened, and intervention measures must be formulated as early as possible to improve the prognosis of patients.PMID:38374010 | DOI:10.56434/j.arch.esp.urol.20247701.4
Source: Archivos Espanoles de Urologia - Category: Urology & Nephrology Authors: Source Type: research